You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epidermal growth factor receptor (EGFR)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)

Available
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
  • (no location specified)
Oct 17, 2023

EGFR Mutation-Related Tumors Trial (NX-019)

Not yet recruiting
  • EGFR Mutation-Related Tumors
  • (no location specified)
Aug 22, 2022

Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
May 23, 2022

Observes Afatinib as First-line Treatment and Sequential Therapy

Active, not recruiting
  • Non-squamous, Non-Small Cell Lung Cancer
  • Beijing, China
  • +9 more
Jan 9, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

Real-world Data of Afatinib Treatment in First-line Setting and

Active, not recruiting
  • Non-squamous, Non-Small Cell Lung Cancer
  • Tokyo, Japan
    Nippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023

PFS Trial in Qingdao (afatinib)

Recruiting
  • PFS
  • Qingdao, Shandong, China
  • +1 more
Feb 23, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 10, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC Trial in Qingdao (Osimertinib Oral Tablet)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Osimertinib Oral Tablet
  • Qingdao, Shandong, China
    Qingdao Central Hospital, Qingdao Cancer Hospital
Nov 1, 2021

NSCLC Trial in Qingdao (osimertinib oral and bevazizumab intravenously)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • osimertinib oral and bevazizumab intravenously
  • Qingdao, Shandong, China
    Qingdao Central Hospital, Qingdao Cancer Hospital
Nov 1, 2021

Lung Cancer Trial in Houston (Ibrutinib)

Completed
  • Lung Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 21, 2021

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

NSCLC (NSCLC) Trial (Dacomitinib+Anlotinib, Dacomitinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Feb 28, 2022

NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +8 more
Jan 31, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)

Not yet recruiting
  • NSCLC
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 28, 2021

Glioblastoma Trial (CM93)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Jun 17, 2021

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

    Active, not recruiting
    • NSCLC Stage IIIB
    • +4 more
    • Hong Kong, Hong Kong
    • +8 more
    Jan 10, 2023

    NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Nov 7, 2023

    Advanced Solid Tumours, NSCLC, Head and Neck Squamous Cell Carcinoma Trial in Singapore (Oral Dacomitinib)

    Recruiting
    • Advanced Solid Tumours
    • +2 more
    • Oral Dacomitinib
    • Singapore, Singapore
    • +1 more
    May 10, 2022

    Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer Trial in Buffalo, Cleveland (Cetuximab,

    Completed
    Has Results
    • Recurrent Colorectal Carcinoma
    • +2 more
    • Cetuximab
    • +2 more
    • Buffalo, New York
    • +1 more
    Sep 29, 2022